Tokyo, Jan. 28 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060481) titled 'Multicenter retrospective study to confirm the efficacy and safety of carbon ion radiotherapy for choroidal malignant melanoma' on Jan. 27.
Study Type:
Observational
Primary Sponsor:
Institute - National Institutes for Quantum Science and Technology (QST)
Condition:
Condition - choroidal malignant melanoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To retrospectively assess the therapeutic efficacy and safety of carbon ion radiotherapy administered to patients with choroidal malignant melanoma, using clinical data collected across multiple institutions, and to analyze factors associated with treatment outcomes.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients who received carbon ion radiotherapy for choroidal malignant melanoma at QST Hospital from April 2001 to March 2024.
Key exclusion criteria - Cases in which the secondary use of clinical data is refused when obtaining consent for treatment or other research, and cases in which the research subject or his/her representative refuses the use of clinical data in this study.
Target Size - 350
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2026 Year 01 Month 12 Day
Date of IRB - 2026 Year 01 Month 12 Day
Anticipated trial start date - 2026 Year 01 Month 27 Day
Last follow-up date - 2026 Year 01 Month 27 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069113
Disclaimer: Curated by HT Syndication.
